Abstract
The cornea maintains avascularity by balancing angiogenic factors and anti-angiogenic agents. Stress on the cornea can disrupt this delicate equilibrium resulting in angiogenesis. Bevacizumab (Avastin®; Genentech, South San Francisco, CA) is a humanized monoclonal antibody which binds to all isoforms of vascular endothelial growth factor (VEGF)-A, thereby inhibiting angiogenesis. Recent studies have explored the role of bevacizumab in treating corneal neovascularization and ocular surface disease. Animal and human studies using both subconjunctival and topical bevacizumab reveal a reduction in corneal neovascularization. Evidence suggests that topical bevacizumab is safe and may be effective in the treatment of corneal neovascularization. Case studies suggest that bevacizumab may be useful in limiting the recurrence of corneal neovascularization when combined with corneal transplant surgery. A few reports have assessed the role of bevacizumab in pterygium surgery as well. These preliminary studies suggest that the use of subconjunctival bevacizumab may be beneficial in the treatment of pterygia but its benefit has not been defined. The role of bevacizumab in corneal and ocular surface disease continues to evolve.
Keywords: Antivascular endothelial growth factor, bevacizumab, cornea, pterygium, corneal neovascularization, infection, degeneration, inflammation, surface disease, lipid keratopathy
Current Drug Therapy
Title:Anti-VEGF Treatment of Anterior Segment Disorders of the Eye
Volume: 7 Issue: 2
Author(s): Saiyid A. Hasan
Affiliation:
Keywords: Antivascular endothelial growth factor, bevacizumab, cornea, pterygium, corneal neovascularization, infection, degeneration, inflammation, surface disease, lipid keratopathy
Abstract: The cornea maintains avascularity by balancing angiogenic factors and anti-angiogenic agents. Stress on the cornea can disrupt this delicate equilibrium resulting in angiogenesis. Bevacizumab (Avastin®; Genentech, South San Francisco, CA) is a humanized monoclonal antibody which binds to all isoforms of vascular endothelial growth factor (VEGF)-A, thereby inhibiting angiogenesis. Recent studies have explored the role of bevacizumab in treating corneal neovascularization and ocular surface disease. Animal and human studies using both subconjunctival and topical bevacizumab reveal a reduction in corneal neovascularization. Evidence suggests that topical bevacizumab is safe and may be effective in the treatment of corneal neovascularization. Case studies suggest that bevacizumab may be useful in limiting the recurrence of corneal neovascularization when combined with corneal transplant surgery. A few reports have assessed the role of bevacizumab in pterygium surgery as well. These preliminary studies suggest that the use of subconjunctival bevacizumab may be beneficial in the treatment of pterygia but its benefit has not been defined. The role of bevacizumab in corneal and ocular surface disease continues to evolve.
Export Options
About this article
Cite this article as:
A. Hasan Saiyid, Anti-VEGF Treatment of Anterior Segment Disorders of the Eye, Current Drug Therapy 2012; 7 (2) . https://dx.doi.org/10.2174/157488512800676011
DOI https://dx.doi.org/10.2174/157488512800676011 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Virulence Factors of Candida albicans Isolates from the Oral Cavities of HIV-1-Positive Patients
Current HIV Research Graves Ophthalmopathy: A Review of Immunogenetics
Current Genomics Peptide Nucleic Acids (PNA)-DNA Chimeras Targeting Transcription Factors as a Tool to Modify Gene Expression
Current Drug Targets The Role of Mediterranean Diet, CoQ10 and Conjugated-Melatonin in Osteoporosis Primary Prevention and Therapy
Current Nutrition & Food Science Current Status of Mucoadhesive Gel Systems for Buccal Drug Delivery
Current Pharmaceutical Design Radiolabelled Oligonucleotides for Imaging of Gene Expression with PET
Current Medicinal Chemistry Nutritional Support in Cancer
Current Nutrition & Food Science Exploring Genetic Influences on Cognition: Emerging Strategies for Target Validation and Treatment Optimization
Current Drug Targets - CNS & Neurological Disorders Human Ghrelin: A Gastric Hormone with Cardiovascular Properties
Current Pharmaceutical Design Structural Design and Physicochemical Foundations of Hydrogels for Biomedical Applications
Current Medicinal Chemistry Is Tretinoin Still a Key Agent for Photoaging Management?
Mini-Reviews in Medicinal Chemistry Proteases and Their Role in Chronic Inflammatory Lung Diseases
Current Drug Targets Nerve Growth Factor: Early Studies and Recent Clinical Trials
Current Neuropharmacology Efficacy and Cardiovascular Safety of Metformin
Current Drug Safety Viral Latent Proteins as Targets for Kaposis Sarcoma and Kaposis Sarcoma-associated Herpesvirus (KSHV / HHV-8) Induced Lymphoma
Current Drug Targets - Infectious Disorders Vascular Arginase and Hypertension
Current Hypertension Reviews Functional Components from Nature-Derived Drugs for the Treatment of Rheumatoid Arthritis
Current Drug Targets Innovative Drug Delivery Systems for the Administration of Natural Compounds
Current Bioactive Compounds Gemini Surfactant Based Carriers in Gene and Drug Delivery
Current Medicinal Chemistry Multiple Functions of Mammalian Germinal Center Kinases
Current Chemical Biology